This 2002 Pain review (NIH-funded, NS40434) synthesizes 32+ references to argue visceral pain differs mechanistically from somatic pain. Key claims: (1) visceral afferents are almost exclusively A-delta and C fibers lacking specialized end organs, innervating via dual vagal and spinal (pelvic/splanchnic) pathways; (2) viscerosomatic and viscerovisceral convergence in the dorsal horn explains poor localization and referred pain; (3) only ~10% of spinal afferent inflow is visceral despite organs' large surface area .
The most consequential claim is the dorsal column (DC) pathway: DC lesions in monkeys dramatically reduced thalamic VPL responses to colorectal distension while spinothalamic tract lesions did not, and DC lesions suppressed spinal sensitization in the neonatal-colon-irritation model . Later work confirmed translational relevance: C1βC2 punctate midline myelotomy in mice reduced acetic-acid writhing from 56.7Β±10.7 (control) to 30.0Β±14.3 (>40% antinociception, p<0.001, n=12/group, blinded observers) .
The second pillar is the neonatal colon irritation model producing adult visceral hyperalgesia with central sensitization (heightened neuronal responses, c-Fos expression in lumbosacral/thoracolumbar segments) and primary afferent sensitization β a developmental-stress paradigm that subsequent work extended: prenatal maternal stress upregulates ASIC1 via promoter demethylation and NF-ΞΊB binding in gastric-projecting DRG neurons, reversing hypersensitivity with amiloride , and maternal separation induces hypersensitivity in wildtype and GABA-B(1b) knockout mice .
Reported observations are electrophysiological and behavioral from rodents and primates; the authors' interpretation that these models "mimic" IBS is an extrapolation β the hyperalgesia-to-IBS inference rests on face validity, not predictive validity, which the review does not address. The kappa-opioid receptor claim of a "novel peripheral site" is honestly caveated by the authors (receptor not cloned; antisense data not conclusive). Notably, the review anticipated mechanistic heterogeneity: NK-1 receptors signal neurogenic but not non-neurogenic inflammation β a prediction borne out by later translational failures of NK1 antagonists. Blind spots: no discussion of sex differences, no human psychophysical validation of the DC pathway claims, and heavy reliance on the authors' own neonatal-irritation model (self-citation concentration risk).
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.